instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
Can you share the median Progression-Free Survival rate in patients who have received No Maintenance regimen? | Patients treated with the No Maintenance have a median Progression-Free Survival (PFS) rate of 21.6 months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received No Maintenance regimen?
### Response: Patients treated with the No Maintenance have a median Progression-Free Survival (PFS) rate of 21.6 months, with a 95% CI of None. |
Can you tell me the median PFS for High-Dose Melphalan+Lenalidomide Maintenance? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for High-Dose Melphalan+Lenalidomide Maintenance?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
What’s the median PFS associated with High-Dose Melphalan+Lenalidomide Maintenance? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with High-Dose Melphalan+Lenalidomide Maintenance?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Could you provide the median PFS of High-Dose Melphalan+Lenalidomide Maintenance? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of High-Dose Melphalan+Lenalidomide Maintenance?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
I’d like to know the median PFS of High-Dose Melphalan+Lenalidomide Maintenance. | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of High-Dose Melphalan+Lenalidomide Maintenance.
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Do you have information on the median PFS of High-Dose Melphalan+Lenalidomide Maintenance? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of High-Dose Melphalan+Lenalidomide Maintenance?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for High-Dose Melphalan+Lenalidomide Maintenance? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for High-Dose Melphalan+Lenalidomide Maintenance?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Can you inform me about the median PFS for High-Dose Melphalan+Lenalidomide Maintenance? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for High-Dose Melphalan+Lenalidomide Maintenance?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
I’m interested in the median PFS of High-Dose Melphalan+Lenalidomide Maintenance. | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of High-Dose Melphalan+Lenalidomide Maintenance.
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Could you tell me the median PFS for High-Dose Melphalan+Lenalidomide Maintenance? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for High-Dose Melphalan+Lenalidomide Maintenance?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
What is the median PFS rate for High-Dose Melphalan+Lenalidomide Maintenance? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for High-Dose Melphalan+Lenalidomide Maintenance?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received High-Dose Melphalan+Lenalidomide Maintenance regimen? | Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received High-Dose Melphalan+Lenalidomide Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 54.7 months, with a 95% CI of None. |
Can you tell me the median PFS for High-Dose Melphalan+No Maintenance? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for High-Dose Melphalan+No Maintenance?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
What’s the median PFS associated with High-Dose Melphalan+No Maintenance? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with High-Dose Melphalan+No Maintenance?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Could you provide the median PFS of High-Dose Melphalan+No Maintenance? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of High-Dose Melphalan+No Maintenance?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
I’d like to know the median PFS of High-Dose Melphalan+No Maintenance. | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of High-Dose Melphalan+No Maintenance.
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Do you have information on the median PFS of High-Dose Melphalan+No Maintenance? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of High-Dose Melphalan+No Maintenance?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for High-Dose Melphalan+No Maintenance? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for High-Dose Melphalan+No Maintenance?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Can you inform me about the median PFS for High-Dose Melphalan+No Maintenance? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for High-Dose Melphalan+No Maintenance?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
I’m interested in the median PFS of High-Dose Melphalan+No Maintenance. | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of High-Dose Melphalan+No Maintenance.
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Could you tell me the median PFS for High-Dose Melphalan+No Maintenance? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for High-Dose Melphalan+No Maintenance?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
What is the median PFS rate for High-Dose Melphalan+No Maintenance? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for High-Dose Melphalan+No Maintenance?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received High-Dose Melphalan+No Maintenance regimen? | Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received High-Dose Melphalan+No Maintenance regimen?
### Response: Patients treated with the High-Dose Melphalan+No Maintenance have a median Progression-Free Survival (PFS) rate of 37.4 months, with a 95% CI of None. |
Can you tell me the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
What’s the median PFS associated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Could you provide the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
I’d like to know the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Do you have information on the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Can you inform me about the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
I’m interested in the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Could you tell me the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
What is the median PFS rate for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance have a median Progression-Free Survival (PFS) rate of 34.2 months, with a 95% CI of None. |
Can you tell me the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
What’s the median PFS associated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Could you provide the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
I’d like to know the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Do you have information on the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Can you inform me about the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
I’m interested in the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Could you tell me the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
What is the median PFS rate for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen? | Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance regimen?
### Response: Patients treated with the Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance have a median Progression-Free Survival (PFS) rate of 21.8 months, with a 95% CI of None. |
Can you tell me the median PFS for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Can you tell me the median PFS for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
What’s the median PFS associated with Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: What’s the median PFS associated with Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Could you provide the median PFS of Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Could you provide the median PFS of Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
I’d like to know the median PFS of Idecabtagene Vicleucel (Ide-Cel). | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: I’d like to know the median PFS of Idecabtagene Vicleucel (Ide-Cel).
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Do you have information on the median PFS of Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Do you have information on the median PFS of Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
What is the median progression-free survival (PFS) for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: What is the median progression-free survival (PFS) for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Can you inform me about the median PFS for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Can you inform me about the median PFS for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
I’m interested in the median PFS of Idecabtagene Vicleucel (Ide-Cel). | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: I’m interested in the median PFS of Idecabtagene Vicleucel (Ide-Cel).
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Could you tell me the median PFS for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Could you tell me the median PFS for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
What is the median PFS rate for Idecabtagene Vicleucel (Ide-Cel)? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: What is the median PFS rate for Idecabtagene Vicleucel (Ide-Cel)?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
What is the median PFS rate in patients who have undergone Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: What is the median PFS rate in patients who have undergone Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
What’s the median PFS rate for patients receiving Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: What’s the median PFS rate for patients receiving Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Could you provide the median Progression-Free Survival rate for patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Subsets and Splits